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Temporal trends of molecular markers associated
with artemether-lumefantrine tolerance/resistance
in Bagamoyo district, Tanzania
Maja Malmberg1*, Billy Ngasala2, Pedro E Ferreira1,3, Erik Larsson1, Irina Jovel1,4, Angelica Hjalmarsson1,
Max Petzold5, Zul Premji2, José P Gil3,6,7, Anders Björkman1 and Andreas Mårtensson1,8
Abstract
Background: Development and spread of Plasmodium falciparum resistance to artemisinin-based combination
therapy (ACT) constitutes a major threat to recent global malaria control achievements. Surveillance of molecular
markers could act as an early warning system of ACT-resistance before clinical treatment failures are apparent. The
aim of this study was to analyse temporal trends of established genotypes associated with artemether-lumefantrine
tolerance/resistance before and after its deployment as first-line treatment for uncomplicated malaria in Tanzania
2006.
Methods: Single nucleotide polymorphisms in the P. falciparum multidrug resistance gene 1 (pfmdr1) N86Y, Y184F,
D1246Y and P. falciparum chloroquine transporter gene (pfcrt) K76T were analysed from dried blood spots collected
during six consecutive studies from children with uncomplicated P. falciparum malaria in Fukayosi village,
Bagamoyo District, Tanzania, between 2004–2011.
Results: There was a statistically significant yearly increase of pfmdr1 N86, 184F, D1246 and pfcrt K76 between
2006–2011 from 14% to 61% (yearly OR = 1.38 [95% CI 1.25-1.52] p < 0.0001), 14% to 35% (OR = 1.17 [95% CI
1.07-1.30] p = 0.001), 54% to 85% (OR = 1.21 [95% CI 1.03-1.42] p = 0.016) and 49% to 85% (OR = 1.33 [95% CI
1.17-1.51] p < 0.0001), respectively. Unlike for the pfmdr1 SNP, a significant increase of pfcrt K76 was observed
already between 2004–2006, from 26% to 49% (OR = 1.68 [95% CI 1.17-2.40] p = 0.005). From 2006 to 2011 the
pfmdr1 NFD haplotype increased from 10% to 37% (OR = 1.25 [95% CI 1.12-1.39] p < 0.0001), whereas the YYY
haplotype decreased from 31% to 6% (OR = 0.73 [95% CI 0.56-0.98] p = 0.018). All 390 successfully analysed
samples had one copy of the pfmdr1 gene.
Conclusion: The temporal selection of molecular markers associated with artemether-lumefantrine tolerance/
resistance may represent an early warning sign of impaired future drug efficacy. This calls for stringent surveillance
of artemether-lumefantrine efficacy in Tanzania and emphasizes the importance of molecular surveillance as a
complement to standard in vivo trials.
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Background
Modern malaria control relies primarily on sustained ef-
ficacy of artemisinin-based combination therapy (ACT).
Reports of artemisinin tolerant/resistant Plasmodium
falciparum from Southeast Asia [1-3] constitute, there-
fore, a major threat to recent global malaria control
achievements. Within the African continent there has to
date been no clear evidence of artemisinin resistance,
but an increased parasite positivity rate on day 1 after
initiation of ACT treatment has been reported from
Kenya [4].
ACT is a combination of an artemisinin derivative,
which rapidly reduces the parasite load, and a long-
acting partner drug that kills the remaining parasites
and suggestively protects the artemisinin component
from resistance development. During clearance of the
long-acting partner drug re-infecting parasites are ex-
posed to slowly declining drug concentrations during
several weeks. This phenomenon, which is of particu-
lar importance in high transmission areas, may be the
starting point for development of tolerance/resistance
towards the long-acting partner drug. This could initially
result in a shorter post-treatment prophylactic effect and
eventually reduce the ACT to an artemisinin derivative
monotherapy.
The most commonly used ACT in Africa is artemether-
lumefantrine. It has been deployed as first-line treatment
for uncomplicated malaria in Tanzania since 2006.
Artemether-lumefantrine has shown to be highly effica-
cious with PCR-corrected cure rates exceeding 95% [5-7].
However, artemether-lumefantrine has been associated
with selection of single nucleotide polymorphisms (SNPs)
in genes associated with anti-malarial drug resistance
among re-infections, as compared with baseline parasite
characteristics [8-10]. The main SNPs are P. falciparum
multidrug resistance gene 1 (pfmdr1) N86, 184F and
D1246 [8,9] and the P. falciparum chloroquine transporter
gene (pfcrt) K76 allele [10]. This highlights the need of
close surveillance of molecular markers as an early warn-
ing system of development and spread of anti-malarial
drug resistance and an important tool for insights into
drug resistance development.
The aim of this study was to assess temporal trends of
molecular markers associated with anti-malarial drug
resistance in a rural Tanzanian village before and af-
ter wide scale deployment of artemether-lumefantrine
as first-line treatment of uncomplicated P. falciparum
malaria.
Methods
Study area
The studies were conducted in Fukayosi village, Bagamoyo
District, Coast region, Tanzania. Fukayosi dispensary
serves a population of approximately 7,000 people. The
catchment area is primarily rural. Malaria transmission
is high and occurs throughout the year with peaks rela-
ted to the rainy seasons in May to July (long rains) and
December to January (short rains). Plasmodium falcip-
arum is the predominant malaria species and Anopheles
gambiae complex the main vector. In 2004, sulphadoxine-
pyrimethamine was first-line treatment and amodiaquine
second-line treatment for uncomplicated malaria. Since
November 2006 artemether-lumefantrine has been the
first-line treatment.
Study design and population
Study 1 was a two-arm (artemether-lumefantrine versus
sulphadoxine-pyrimethamine) efficacy trial conducted in
2004 [6]. Study 2 was an artemether-lumefantrine phar-
macokinetic and pharmacodynamics study performed in
2006 [11]. Study 3 was a two-arm (efficacy versus effect-
iveness) artemether-lumefantrine clinical trial conducted
in 2007 [7]. Study 4, Study 5 and Study 6 represent pre-
treatment blood samplings done in 2008, 2010 and 2011,
respectively (unpublished data). In total, 777 patients
were included in the present analysis.
The study population consisted of children ≤10 years
with symptomatic, uncomplicated, microscopy confirmed
P. falciparum infection. Detailed inclusion and exclusion
criteria for Studies 1 to 3 have been reported elsewhere
[5,7,11]. A brief descriptive summary of study population
is presented in Table 1.
Biological material
Blood spots were collected on filter paper (Whatman 3
MM) just prior to initiation of anti-malarial treatment,
dried and put in individual zipper plastic bags. There-
after, they were transported to Karolinska Institutet,
Sweden, for molecular analysis.
Molecular analysis
DNA extraction and analysis
Genomic DNA was extracted from the dried blood spots
using the BloodPrep™ Chemistry on an ABI PRISMW
6100 (Applied Biosystems™, Fresno, CA, USA) accord-
ing to the manufacturer’s instructions, and analysed by
PCR for the presence of different genetic markers associ-
ated with anti-malarial drug resistance.
Genotyping of pfmdr1 and pfcrt
Pfmdr1 N86Y and pfcrt K76T were genotyped using
PCR-RFLP according to previously described protocol
[12]. Restriction fragments were loaded on 2% agarose
gels containing 0.1 μg/ml ethidium bromide, separated
by electrophoresis and visualized under UV transillu-
mination (GelDoc System, Biorad, Hercules, CA, USA).
Pfmdr1 Y184F was analysed by pyrosequencing in Study
1 [13], sequencing in Studies 2 and 3 [14] and PCR-
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RFLP in Studies 4, 5 and 6. Pfmdr1 D1246Y was analysed
by PCR-RFLP in Studies 1, 4, 5 and 6 [13], pyrosequencing
in Study 2 and sequencing in Study 3 [15]. To maintain
consistency in the analysis of mixed infections, samples
from Study 2 were analysed by pyrosequencing (pfmdr1
D1246Y, pfmdr1 Y184F), together with a dilution series of
mixed DNA in different proportions from the clones 7G8
(pfmdr1 1246Y, pfmdr1 184F carrier) and 3D7 (pfmdr1
D1246, pfmdr1 Y184 carrier). Samples with more than
10% of each allele at a particular locus were defined as
mixed infections. The cut off values were used to re-assess
the data from Study 1 [10] to ensure consistency.
Sequencing was done by Macrogen Inc (Seoul,
Korea), Sequencher™ software version 4.6 (Gene Codes
Corporation, Ann Arbor, MI, USA) was used to analyse
the sequences with 3D7 as the pfmdr1 reference se-
quence (PFE1150w, Gene ID 813045 at NCBI RefSeq,
National Center for Biotechnology Information Refer-
ence Sequence). The PCR success rates for pfmdr1
N86Y, Y184F, D1246Y and pfcrt K76T were 97% (752/
777), 96% (749/777), 95% (740/777) and 96% (749/
777), respectively.
pfmdr1 copy number variation
In Study 1, 2, 3 and partly Study 4, pfmdr1 copy number
was assessed using TaqmanW based real-time PCR (ABI
PrismW 7000) [16]. β-tubulin was used as one copy en-
dogenous control. The clones 3D7, K1, D10, all with one
copy of pfmdr1, were used as calibrators. Dd2 and FCB
were used as multi-copy controls. All samples were run
in triplicates. PCR success rates were 84% (89/106), 96%
(48/50), 81% (208/258) and 90% (45/50) for Studies 1, 2,
3 and 4, respectively.
Ethical considerations
Before enrolment, written informed consent was
obtained from parents/legal guardians of the children.
The studies were approved by the National Institute for
Medical Research, Tanzania and Karolinska Institutet
Ethical Review Board or the Regional Ethics Committee,
Stockholm, Sweden. Studies 2 and 3 were registered with
identifier NCT00336375 [17] and ISRCTN69189899
[18], respectively.
Statistical analysis
For prevalence analysis of individual SNPs, mixed infec-
tions (both alleles present at a particular locus) were
analysed together with the polymorphism not associated
with lumefantrine tolerance/resistance, i.e., pfmdr1 86Y,
Y184, 1246Y and pfcrt 76 T. For haplotype analysis, mi-
nority haplotypes (≤ 5%) and infections that were mixed
at two or more loci were excluded. Infections that were
mixed at only one locus were analysed as having both
haplotypes. The combined pfmdr1 and pfcrt haplotype
was made based on the pfmdr1 haplotypes.
Logistic regression with year included as a continu-
ous covariate was used to estimate the yearly changes
in prevalence. The presented odds ratios (OR) with
corresponding 95% confidence intervals (CI) repre-
sent the relative change per year. The 2006 study,
conducted in June, i.e., just prior to artemether-
lumefantrine deployment, was used as baseline for
trend analysis. Statistical significances were confirmed
using non-parametric trend test. STATA v. 12 was used
for all analysis, figures were made in SigmaPlotW 11,
p-values were estimated using bootstrapping (100 re-
peats) and a p-value <0.05 was considered statistically
significant.
Results
Description of study population
A total of 777 patients were included in the analysis.
The details of the study population are presented in
Table 1. The blood slide positivity rate for Study 5 was
lower (17%) compared with the mean all other studies
combined (53%).
Table 1 Base line characteristics of the study population
Study 1 Study 2 Study 3 Study 4 Study 5 Study 6
Year 2004 2006 2007 2008 2010 2011
Study period May Jun May – Nov Aug-Oct Oct-Dec + Jan
2011
Apr-Jun
Patients included (n) 106 50 258 200 33 130
Sex, female patients (%) 51 62 54 49 49 50
Age, months, median (range) 31 (6–135) 48 (12–119) 31 (4–60) 36 (2–124) N.D 60 (12–120)
Weight, kg, median (range) 12 (6–33) 13 (8–30) 12 (5–21) 12 (5–33) 13 (6–29) 15 (8–32)
Parasites/μL, geometric mean (range) 21,595 (2,000-
160,000)
36,885 (2,120-
200,400)
43,259 (2,700-
192,320)
17,531 (2,000-
192,000)
18,537 (2,400-
185,120)
10,198 (1,080-
112,800)
Slide positivity rate, microscopy
positive/screened (%)
175/434 (40%) 148/277 (53%) 718/1403 (51%) 473/745 (63%) 99/588 (17%) 599/1002 (60%)
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Temporal trends in the prevalence of SNPs in pfmdr1 and
pfcrt SNPs
There was a statistically significant increase of pfmdr1
N86, 184F and D1246 over the time period 2006 to 2011
from 14% to 61% (yearly OR = 1.38 [95% CI 1.25-1.52]
p < 0.0001), 14% to 35% (OR = 1.17 [95% CI 1.07-1.30]
p = 0.001) and 54% to 85% (OR = 1.21 [95% CI 1.03-
1.42] p = 0.016), respectively (Figure 1, Table 2). No sig-
nificant yearly change was observed between 2004 and
2006. During the same time period there was a signifi-
cant increase of pfcrt K76 from 49% pre-AL to 85%
(OR = 1.33 [95% CI 1.17-1.51] p < 0.0001). However, a
significant increase of pfcrt K76 was observed already
between 2004–2006, from 26% to 49% (OR = 1.68 [95%
CI 1.17-2.40] p = 0.005).
pfmdr1 haplotypes
The prevalences of pfmdr1 haplotypes at codon N86Y,
Y184F, D1246Y during 2004–2011 are presented in
Figure 2. There was a statistically significant increase of
NFD haplotype between 2006–2011 from 10% to 37%
(OR = 1.25 [95% CI 1.12-1.39] p < 0.0001). During the
same period the NYD showed a trend of increase from
18% to 35% (OR = 1.10 [95% CI 0.98-1.23] p = 0.098).
The YYD and YYY haplotypes decreased significantly
2006 to 2011 from 44% to 21% (OR = 0.79 [95% CI 0.68-
0.90] p < 0.0001) and 31% to 6% (OR = 0.73 [95% CI
0.56-0.98] p = 0.018), respectively.
The combined pfmdr1 and pfcrt haplotypes
There was a statistically significant increase of the
NFD + K haplotype from 12% to 36% (OR 1.27 [95% CI
1.12-1.45] p < 0.0001) between 2006–2011. During the
same period the NYD + K haplotype increased from 7%
to 28% (OR 1.10 [95% CI 0.97-1.25] p = 0.127). Between
2006 and 2011 there was a significant decrease of the
YYD + K and YYD + T from 29% to 20% (OR 0.86 [95%
CI 0.74-1.00] p = 0.041) and 17% to 0% (OR 0.59 [95%
CI 0.41-0.83] p = 0.003), respectively. During the same
time period there was a decrease in prevalence of YYY +T
from 19% to 2% (OR 0.63 [95% CI 0.39-1.00] p = 0.05).
This decrease was statistically significant by non-
parametric trend test (p = 0.003) (Table 3).
pfmdr1 copy number variation
All 390 successfully analysed samples had one copy of
the pfmdr1 gene.
Discussion
This study provides evidence for a continuous selec-
tion of molecular markers associated with artemether-
lumefantrine tolerance/resistance in the local P. falciparum
population in Fukayosi village, Bagamoyo district,
Tanzania, occurring after the introduction of this ACT
as first-line treatment for uncomplicated malaria in
2006.
The results support previous observations of pfmdr1
N86 selection in Gabon, Kenya and Mozambique
[19-21] as well as selection of both pfmdr1 N86 and
184F in Korogwe, Tanzania [22], and the pfmdr1 N86,
184F, D1246 haplotype in Mozambique [23] following
wide scale deployment of artemether-lumefantrine.
However, the present report adds substantially to the
evidence base being more comprehensive both with
regards to number of patients and genetic markers
analysed, and importantly with a longer duration of
follow-up.
Interestingly the selection of pfcrt K76 started already
prior to the introduction of artemether-lumefantrine in
Bagamoyo district. This probably represents an effect of
Figure 1 Temporal trends of PfMDR1 N86Y, Y184F, D1246Y and
PfCRT K76T. Temporal trends (means and 95% confidence intervals)
of A) PfMDR1 N86, 184F, D1246 and B) PfCRT K76 during 2004–2011
in Fukayosi village, Bagamoyo District, Tanzania. Mixed infections
(both alleles present at a particular locus) were analysed together
with the polymorphism not associated with lumefantrine tolerance/
resistance, i.e., PfMDR1 86Y, Y184, 1246Y and PfCRT 76 T. The arrow
indicates when artemether-lumefantrine has been first-line
treatment.
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the withdrawal of chloroquine as first-line treatment
in 2001, consistent with observations from Malawi
where withdrawal of chloroquine resulted in a fast re-
expansion of a diverse chloroquine-susceptible pfcrt K76
population [24]. Thus, the herein observed increase in
pfcrt K76 may not necessarily only be due to the intro-
duction of artemether-lumefantrine, but could also, at
least partly, be explained by the withdrawal of chloro-
quine and/or other factors, such as parasite fitness and
transmission intensity [24-26]. Conversely, no selection
of pfmdr1 N86, 184F, D1246 occurred prior to introduc-
tion of artemether-lumefantrine in the study area. The
selection of these SNPs seen after 2006 is therefore
unlikely driven by the withdrawal of chloroquine.
There are evidences that exposure of artemether-
lumefantrine is the main contributor behind the ob-
served selection of pfmdr1 N86, 184F, D1246 SNPs and
that it plays a role also for selection of pfcrt K76. These
evidences include the previously reported specific
lumefantrine-driven selection among re-infections dur-
ing follow up after artemether-lumefantrine treatment
[9,10], in vitro findings [27] and a recent study con-
ducted in Tanzania, which shows that the selection of
N86, 184F and D1246 after artemether-lumefantrine
Figure 2 Temporal trends of PfMDR1 haplotypes. Prevalences of PfMDR1 haplotypes at codon N86Y, Y184F, D1246Y in Fukayosi village,
Bagamoyo District, Tanzania, from 2004–2011. Minority haplotypes (≤ 5%) and infections that were mixed (both alleles present at a particular
locus) at 2 two or more loci were excluded. Infections that were mixed at only one locus were analysed as having both haplotypes. The arrow
indicates when artemether-lumefantrine has been first-line treatment for uncomplicated malaria.
Table 2 Prevalences of pfmdr1 and pfcrt SNPs in Fukayosi village, Bagamoyo District, Tanzania, from 2004-2011
Gene Mutation Study 1 Study 2 Study 3 Study 4 Study 5 Study 6
2004 2006 2007 2008 2010 2011
n= (%) n= (%) n= (%) n= (%) n= (%) n= (%)
pfmdr1 N86 27 26.5 7 14 94 36.6 115 61.1 23 74.2 76 61.3
mix-86 30 29.4 19 38 71 27.6 27 14.4 3 9.7 20 16.1
86Y 45 44.1 24 48 92 35.8 46 24.5 5 16.1 28 22.6
184F 8 8 7 14 61 23.9 46 24.7 10 32.3 44 34.9
mix-184 17 17 6 12 30 11.8 23 12.4 8 25.8 15 11.9
Y184 75 75 37 74 164 64.3 117 62.9 13 41.9 67 53.2
D1246 50 51 26 54.2 202 79.8 158 85.9 27 84.4 106 84.8
mix-1246 24 24.5 14 29.2 20 7.9 15 8.1 4 12.5 14 11.2
1246Y 24 24.5 8 16.7 31 12.3 11 6 1 3.1 5 4
pfcrt K76 26 25.5 24 49 167 65 128 68.4 23 74.2 104 84.6
mix-76 23 22.5 11 22.5 43 16.7 28 15 2 6.5 5 4.1
76T 53 52 14 28.6 47 18.3 31 16.6 6 19.4 14 11.4
N = asparagine, Y = tyrosine, F = phenylalanine, D = aspartic acid, mix = the presence of both alleles at one loci.
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treatment in vivo is significantly associated with the abil-
ity to withstand higher lumefantrine concentrations [15].
In this context it is also worth noting that there are
studies suggesting that both the artemisinin-derivatives
and lumefantrine select for the same molecular markers
[28,29]. This, together with the recent evidence from
Southeast Asia that P. falciparum is able to develop arte-
misinin tolerance/resistance, is of particular concern as
it could result in an additive or even synergistic selection
of molecular markers of anti-malarial drug resistance in
the parasite population.
It is of note that the blood slide positivity rate in Study
5 was lower (17%) compared with the mean for all other
studies combined (53%). This may be due to that Study
5 was conducted during October-January, when the mal-
aria transmission is relatively low. However, this did not
appear to have influenced the SNP prevalences. Further-
more, it is important to underline that clinical efficacy of
artemether-lumefantrine remained high in the study area
with PCR-corrected cure rate >95% in 2007 [7]. Never-
theless, in an era when the number of malaria patients is
slowly declining, standard in vivo trials are increasingly
difficult and costly to conduct. In this context, molecular
surveillance may play an important role to detect selec-
tion of genetic markers associated with ACT tolerance/
resistance in the local P. falciparum population over
time.
Conclusions
Increased prevalence of pfmdr1 N86, 184F, D1246 and
pfcrt K76 was observed in the parasite population after de-
ployment of artemether-lumefantrine as first-line treat-
ment for uncomplicated malaria. The pfmdr1 haplotype
NFD increased significantly at the cost of YYY and YYD.
The temporal selection of molecular markers associated
with artemether-lumefantrine tolerance/resistance may
represent an early warning sign of impaired future drug
efficacy. This calls for stringent surveillance of artemether-
lumefantrine efficacy in Tanzania and emphasizes the im-
portance of molecular surveillance as a complement to
standard in vivo trials.
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Table 3 Prevalences of the combined pfmdr1 and pfcrt haplotypes in Fukayosi village, Bagamoyo district, Tanzania,
from 2006-2011
Haplotype 2006 2007 2008 2010 2011 Yearly
OR
95% CI p-value logistic
regression
p-value non-
parametric trend test
NFD + K 12% (5/42) 20% (46/234) 21% (40/188) 37% (13/35) 36% (43/120) 1.27 1.12-1.45 0.000 0.000
NYD + K 7% (3/42) 23% (53/234) 36% (68/188) 29% (10/35) 28% (34/120) 1.10 0.97-1.25 0.127 0.093
YYD + K 29% (12/
42)
27% (64/234) 14% (27/188) 9% (3/35) 20% (24/120) 0.86 0.74-1.00 0.041 0.022
YYY + K 10% (4/42) 7% (16/234) 4% (7/188) 0% (0/35) 4% (5/120) 0.79 0.59-1.06 0.110 0.079
NFD + T 0% (0/42) 5% (12/234) 5% (10/188) 9% (3/35) 3% (3/120) 0.96 0.76-1.21 0.732 0.746
NYD + T 7% (3/42) 5% (12/234) 8% (15/188) 6% (2/35) 8% (9/120) 1.05 0.87-1.26 0.624 0.640
YYD + T 17% (7/42) 7% (17/234) 7% (14/188) 6% (2/35) 0% (0/120) 0.59 0.41-0.83 0.003 0.000
YYY + T 19% (8/42) 6% (14/234) 4% (7/188) 6% (2/35) 2% (2/120) 0.63 0.39-1.00 0.050 0.003
The haplotypes refers to amino acid positions pfmdr1 N86Y, Y184F, D1246Y and pfcrt K76T. Yearly OR is the Odds Ratio for logistic regression 2006 until 2011 with
year included as a continuous covariate. The OR can thus be interpreted as the relative change per year. N = asparagine, Y = tyrosine, F = phenylalanine,
D = aspartic acid, K = lysine, T = threonine.
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